What is a clinical trial?
Clinical trials provide the latest in medical treatments for cancer before they are made available to the general public as standard treatment. Treatments are administered under carefully controlled conditions, which allow doctors and researchers to learn about their effectiveness, as well as possible side effects. Patients are carefully selected, to be sure the treatment is appropriate for their particular disease and current state of health. Participants will work with doctors and health care professionals at every stage of a clinical trial.
Some patients choose to participate in clinical trials in hopes of a better response to treatment or increase in survival by using newer drugs or therapies. Some patients feel that participation in clinical trials will help others - family, friends, or even strangers - as well as themselves. Many patients feel the close follow-up and re-testing schedules used to check results of the treatment on a clinical trial ensures a thorough schedule of care.
Participate in a clinical trial
Review the open clinical trials below. To determine if you are eligible, or for more information, contact Beth Davis at (707) 523-7316 or davismb1 (at) sutterhealth.org.
- Phase II Trial of Single Agent MEK Inhibitor CSK1120212 vs. 5-FU or Capecitabine in Refractory Advanced Biliary Carcinoma
- Randomized, Double-Blind, placebo-controlled trial of adjuvant endocrine therapy plus or minus 1 year of Everolimus in patients with high-risk, receptor positive HER2 negative breast cancer.
- A Phase III trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER2-positive ductal carcinoma in situ resected by lumpectomy
- A phase III randomized trial of adjuvant therapy comparing chemotherapy alone (six cycles of TC or four cycles of AC followed by four cycles of weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-normal invasive breast cancer
- Neoadjuvant treatment of post-menopausal women with ER/PR positive, HER2 negative breast cancer using Letrozole and BYL719 or buparlisib Phase III randomized, post-mastectomy chest wall and nodal radiation therapy and post-lumpectomy nodal radiation therapy in patients with positive axillary nodes before neo-adjuvant chemotherapy who convert to pathologically negative axillary nodes after neo-adjuvant chemotherapy
- Phase III randomized, placebo-controlled trial of adjuvant endocrine therapy plus or minus 1 year of everolimus in patients with high-risk HER2 + breast cancer
- Placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancer in patients with stage 0-III colon cancer
- A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer
- Randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of darbepoetin alfa every three weeks in stage IV lung cancer anemic patients
- Expanded Access Program of PD-1 in Metastatic Melanoma Patients with Limited or No Treatment Options.
- Phase II multi-center, open-label trial to evaluate the safety and efficacy of talimogene laheroparepvec and Ipilimumab compared to Ipilimumab alone in subjects with previously untreated, unresected, Stage IIIB-IV melanoma
- Phase II Randomized study comparing 2 doses of Carfilzomib with dexamethasone for multiple myeloma patients with relapsed or refractory disease
- Randomized Study Comparing 2 Doses of Carfilzomib with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease.
- Randomized open-label study of pomalidomide, Velcade + low-dose dexamethasone versus Velcade + low-dose dexamethasone
- Lenalidomide and rituximab in patients with previously untreated indolent NHL lymphoma
- Randomized Phase II study of temozolomide or temozolomide/capecitabine in patients with advanced pancreatic neuroendocrine tumors
- Ph 2 randomized trial comparing androgen deprivation treatment plus TAK-700 with androgen deprivation plus bi8calutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer
- Randomized Phase 3 study of neo-adjuvant docetaxel and androgen deprivation prior to radical prostatectomy vs. immediate radical prostatectomy in patients with high-risk, clinically localized prostate cancer
- EVErolimus for Renal Cancer. A Phase III Study. (Intermediate, High Risk or Very High Risk)
- Randomized Phase III trial of lenalidomide vs. observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.
- A Phase III, randomized, double-blinded study comparing gemcitabine, cisplatin, and bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced transitional cell carcinoma